The company has opened its first manufacturing facility in India (Manesar) at an investment of Rs 150 crore. It also plans to accelerate its export strategy in the Asia pacific region with the launch of this unit for manufacturing care diagnostic products.
"We have been doing very well in India in last several years focusing on our three core areas -- cardiometabolic disease, infectious disease and toxicology and we intend to achieve the revenue target around all three base businesses," Alere Inc CEO & President Namal Nawana told PTI.
The company had generated a revenue of Rs 300 crore from India last year.
Apart from catering to the Indian market, the company will also be exporting to the neighboring countries in South Asia, he added.
"Alere is committed to improving access to affordable rapid diagnostics in India and throughout the Asia Pacific region through this new world-class manufacturing facility," Nawana said.
The new factory will produce rapid tests for infectious diseases, including Malaria, Dengue and HIV and export them across Asia Pacific, a region heavily impacted by these diseases, he added.
The new facility will support the goals of 'Make in India' initiative, which seeks to transform the country into a global manufacturing hub, Nawana said.
Point of care testing helps improve outcomes and increase the speed of care by bringing the test results within minutes.
When asked about the announced acquisition of Alere by Abbott, Nawana said: "We anticipate that in next few months we would merge."
Alere is a global leader in point of care diagnostics delivering more than 1.4 billion tests in 2015.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
